Associated Papers
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients.
Ruglioni M et al.
Translational Oncology, 2025
Advances in the diagnosis and treatment of MET-variant digestive tract tumors.
Zhang C et al.
World Journal of Gastrointestinal Oncology, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M et al.
Human Mutation, 2022
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Le X et al.
Jco Precision Oncology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W et al.
Cancer Science, 2019
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2017
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Cortot AB et al.
Journal of the National Cancer Institute, 2017
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB et al.
Investigational New Drugs, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL et al.
Biochemistry, 2009
Inhibitory effect of c-Met mutants on the formation of branching tubules by a porcine aortic endothelial cell line.
Maemura M et al.
Cancer Science, 2006
Different point mutations in the met oncogene elicit distinct biological properties.
Giordano S et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2000
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P et al.
Oncogene, 1999